ArticleClinical and experimental immunology2023

Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage.

Teresina Laragione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.